


## Synthetic Studies Towards Halichondrins: Synthesis of the Left Half of Halichondrins

Keith R. Buszek, Francis G. Fang, Craig J. Forsyth, Sung Ho Jung, Yoshito Kishi\*,  
Paul M. Scola, Suk Kyoonyoon


Department of Chemistry, Harvard University, Cambridge, Massachusetts 02138, U.S.A.

**Abstract:** An efficient synthesis of the left half of halichondrins B and C is reported.

Marine natural products halichondrins B and C share a common structure on the left side.<sup>1</sup> In this letter, we report an efficient synthesis of the left half of these halichondrins.




Scheme 1 outlines the synthesis of the C.44-C.54 segment of halichondrin B.<sup>1</sup> The conjugate addition of methylcuprate to the  $\alpha,\beta$ -unsaturated  $\gamma$ -lactone **1**, readily available from L-ascorbic acid,<sup>2</sup> yielded the single stereoisomer **2** in 95% yield.<sup>3</sup> Routine functional group manipulation allowed the transformation of **2** into the epoxide **3**, which was then coupled under Yamaguchi conditions<sup>4</sup> with the acetylene **4**, readily prepared from D-malic acid.<sup>5</sup> Lindlar reduction of the coupled product gave the *cis*-olefin **5** in 86% overall yield from **3**. The *cis*-olefin **5** was then subjected to Sharpless epoxidation<sup>6</sup>, followed by acid treatments, to yield the expected tetrahydrofuran **6** in 61% overall yield with a 7~8:1 stereoselectivity. The stereoselectivity of this epoxidation depended sharply on solvents, with a general trend of aromatic solvents giving more satisfactory results.



### Scheme 1. Reagents and Reaction Conditions.

(a) 1.  $\text{Me}_2\text{CuLi/TMSCl/THF}/-78^\circ\text{C}\rightarrow\text{RT}$ . (b) 1.  $\text{LAH/Et}_2\text{O}/0^\circ\text{C}$ . 2.  $\text{PvCl/Py}/\text{CH}_2\text{Cl}_2/\text{RT}$ . 3.  $p\text{-MeOC}_6\text{H}_4\text{CH}_2\text{-Br}$  (MPM-Br)/ $\text{KH/THF/RT}$ . 4.  $\text{AcOH-H}_2\text{O}$  (4:1)/ $\text{RT}$ . 5.  $\text{NaH/THF/RT}$ , followed by treatment with  $p\text{-Tslmd/THF/RT}$ . (c) 1.  $4/n\text{-BuLi/THF}/-78^\circ\text{C}$ , followed by  $\text{BF}_3\cdot\text{Et}_2\text{O}$  at  $-78^\circ\text{C}$  then addition of **3** at  $-78^\circ\text{C}$ . 2.  $\text{H}_2/\text{Lindlar catalyst/quinoline/hexanes/RT}$ . (d) 1.  $t\text{-BuOOH/VO(acac)}_2/\text{C}_6\text{H}_6/\text{RT}$ . 2.  $\text{TFA/CH}_2\text{Cl}_2/\text{RT}$ . 3.  $\text{AcOH-H}_2\text{O}$  (4:1)/ $\text{RT}$ .

The C.50 and C.51 stereochemistry of **6** was assigned on the basis of literature precedents known for the stereochemical outcome of this type of epoxidation.<sup>7</sup> This assignment was further confirmed by degradation of **7**<sup>8</sup> to **8** and correlation of **8** with the authentic sample prepared *via* a different route (Scheme 2).




### Scheme 2. Reagents and Reaction Conditions.

(e) 1.  $\text{C}_6\text{H}_5\text{CH}_2\text{Br}$  (1 equiv)/ $\text{NaH/THF/RT}$ , and chromatographic separation. 2.  $\text{Ac}_2\text{O/Py/RT}$ . 3.  $\text{AcOH-H}_2\text{O}$  (4:1)/ $\text{RT}$ . 4.  $\text{NaIO}_4/\text{H}_2\text{O-THF}$  (1:1)/ $\text{RT}$ , followed by  $\text{NaBH}_4/\text{MeOH}/0^\circ\text{C}$ . 5.  $o\text{-O}_2\text{NC}_6\text{H}_4\text{SeCN}/n\text{-Bu}_3\text{P/THF/RT}$ , followed by 30%  $\text{H}_2\text{O}_2/\text{THF/RT}$  treatment<sup>10</sup>. 6.  $\text{O}_3/\text{MeOH-CH}_2\text{Cl}_2/-78^\circ\text{C}$ , followed by  $\text{NaBH}_4$  reduction. 7.  $\text{K}_2\text{CO}_3/\text{MeOH/RT}$ . (f) 1.  $t\text{-BuOOH}/(+)\text{-diethyl tartrate/Ti}(\text{i-PrO})_4/\text{CH}_2\text{Cl}_2/-15^\circ\text{C}$ <sup>11</sup>. 2.  $\text{CSA/THF-H}_2\text{O}$  (20:1)/ $\text{RT}$ .


The synthesis outlined in Scheme 1 was designed to specifically address the stereochemical issue of the C.50-C.54 moiety of halichondrin B. The C.50, C.51 and C.53 stereochemistry of halichondrin B was suggested on the basis of vicinal  $^1\text{H-}^1\text{H}$  coupling constants, as well as biogenetic considerations,<sup>1</sup> yet there remained some ambiguity. This synthetic route allowed the preparation of all the stereoisomers with respect to the C.50, C.51 and C.53 stereocenters, by using Sharpless<sup>6</sup> or MCPBA<sup>12</sup> epoxidation of the *cis*- and *trans*-olefins prepared from the acetylene **4** and its antipode. Examination of the chemical shifts and vicinal

Table 1.  $^1\text{H}$  NMR data ( $\text{CD}_3\text{OD}$ ) of **6**, **10**, and halichondrin B

	<b>6</b>	<b>10</b>	halichondrin B <sup>1</sup>
C.50	3.99 (ddd, 9.1, 4.9, 4.2)	4.11 (ddd, 9.2, 6.7, 4.5)	4.00 (9.0, 4.2, 4.2)
C.51	3.73 (ddd, 8.3, 6.1, 4.9)	3.63 (ddd, 8.8, 4.5, 4.1)	3.78 (ddd, 8.7, 4.2, 4.2)
C.52	1.70 (ddd, 13.9, 6.1, 4.7)	1.61 (ddd, 14, 8.8, 7.8)	1.61 (ddd, 14.1, 8.7, 8.3)
C.52	1.75 (ddd, 13.9, 8.3, 8.0)	1.66 (ddd, 14, 5.1, 4.1)	1.75 (14.1, 4.2, 4.2)
C.53	3.83 (dddd, 8.0, 6.2, 4.7, 4.1)	3.86 (dddd, 7.8, 6.0, 5.1, 4.3)	3.87 (m)



spin-spin coupling constants in the  $^1\text{H}$  NMR spectra of stereoisomers thus obtained clearly demonstrated that the  $^1\text{H}$  NMR data observed for **6** and its diastereomer **10** matched well with the reported values<sup>1</sup> for halichondrin B (Table 1). Therefore, these two stereoisomers were separately brought up to the left half **13**<sup>13</sup> of halichondrins B and C and its corresponding diastereomer (Scheme 3), then to the final products.<sup>14</sup>



### Scheme 3. Reagents and Reaction Conditions.

(g) 1. TBSOTf/ $\text{Et}_3\text{N}$ / $\text{CH}_2\text{Cl}_2$ /RT. 2. same as step b.1. (h) 1. Dess-Martin reagent<sup>16</sup>/ $\text{CH}_2\text{Cl}_2$ /RT. 2.  $\text{12}^{15}$ / $t\text{-BuLi}$ / $\text{Et}_2\text{O}$ / $-78^\circ\text{C}$ , followed by treatment with the aldehyde at  $-78^\circ\text{C}$ . 3.  $\text{AgNO}_3$  (6 equiv)/HMDS (7 equiv)/ $\text{H}_2\text{O}$ - $\text{EtOH}$  (1:4)/RT. 4.  $n\text{-Bu}_3\text{SnH}$ /AIBN/toluene/ $80^\circ\text{C}$ . 5.  $\text{I}_2$ / $\text{CH}_2\text{Cl}_2$ /RT. 6. same as step h.1.

**Acknowledgement.** Financial support from the National Institutes of Health (CA-22215) is gratefully acknowledged. We thank the National Institutes of Health for Postdoctoral Fellowships to F.G.F. (CA 08515), C.J.F. (CA 08655), and P.M.S. (GM 13631).

## References and Footnotes

- (a) Uemura, D.; Takahashi, K.; Yamamoto, T.; Katayama, C.; Tanaka, J.; Okumura, Y.; Hirata, Y. *J. Am. Chem. Soc.* **1985**, *107*, 4796-4798. (b) Hirata, Y.; Uemura, D. *Pure & Appl. Chem.* **1986**, *58*, 701-710.
- Vekemans, J. A. J. M.; Franken, G. A. M.; Dapperens, C. W. M.; Godefroi, E. F.; Chittenden, G. J. F. *J. Org. Chem.* **1988**, *53*, 627-633.
- Satisfactory spectroscopic data ( $^1\text{H}$  and  $^{13}\text{C}$  NMR, HRMS, MS, IR, UV,  $[\alpha]_{\text{D}}$ ) were obtained for all new compounds reported in this paper.
- Yamaguchi, M.; Hirao, I. *Tetrahedron Lett.* **1983**, *24*, 391-394.
- The acetylene **4** was synthesized from D-(+)-malic acid in 4 steps, 1.  $\text{BH}_3\cdot\text{Me}_2\text{S}/\text{B}(\text{OMe})_3/\text{THF}/0\text{ }^\circ\text{C}\rightarrow\text{RT}$ , 2. acetone/*p*-TsOH/RT, 3. Swern oxidation [Omura, K.; Swern, D. *Tetrahedron* **1978**, *34*, 1651-1660; Mancuso, A. J.; Huang, S.-L.; Swern, D. *J. Org. Chem.* **1978**, *43*, 2480-2482], 4. DAMP/*t*-BuOK/THF/-78  $^\circ\text{C}$  [Colvin, E. W.; Hamill, B. J. *J. C. S. Chem. Comm.* **1973**, 151-152 and *J. C. S. Perkin I* **1977**, 869-874; Gilbert, J. C.; Weerasooriya, *J. Org. Chem.* **1979**, *44*, 4997-4998], in 25% overall yield.
- (a) Sharpless, K. B.; Michaelson, R. C. *J. Am. Chem. Soc.* **1973**, *95*, 6136-6137. (b) Tanaka, S.; Yamamoto, H.; Nozaki, H.; Sharpless, K. B.; Michaelson, R. C.; Cutting, J. D. *J. Am. Chem. Soc.* **1974**, *96*, 5254-5255.
- For example, see: (a) Sharpless, K. B.; Verhoeven, T. R. *Aldrichimica Acta* **1979**, *12*, 63-74. (b) Kishi, Y. *Aldrichimica Acta* **1980**, *13*, 23-30.
- This correlation was carried out on the substrate with R=TBDPS. The acetamide **7** was the product at the step corresponding to step d.2 in Scheme 1. Then, **7** (R=TBDPS) was converted to **11** to complete the correlation.
- The *cis*-olefin **9** was synthesized from **3** in 4 steps, 1 and 2: same as steps c.1 and c.2 in Scheme 1 with  $\text{TBSOCH}_2\text{C}\equiv\text{CH}$  instead of **4**, 3.  $\text{BnBr}/\text{NaH}/\text{THF}/\text{RT}$ , 4. *p*-TsOH $\cdot$ Py/McOH- $\text{CH}_2\text{Cl}_2$  (1:4)/RT.
- Sharpless, K. B.; Young, M. W. *J. Org. Chem.* **1975**, *40*, 947-949.
- Katsuki, T.; Sharpless, K. B. *J. Am. Chem. Soc.* **1980**, *102*, 5974-5976.
- MCPBA epoxidation of these olefins gave the inverse stereoselectivity of VO(acac) $_2$ -catalyzed epoxidation; for example, MCPBA oxidation of **5** in  $\text{CH}_2\text{Cl}_2$  at RT gave a 3:1 mixture of epoxides. For examples similar to this case, see ref 7.
- $^1\text{H}$  NMR ( $\text{C}_6\text{D}_6$ ) of **13**:  $\delta$  0.01 (3 H, s), 0.02 (3 H, s), 0.14 (6 H, s), 0.25 (3 H, s), 0.26 (3 H, s), 0.27 (3 H, s), 0.28 (3 H, s), 0.87 (3 H, d,  $J = 6.8$  Hz), 0.96 (9 H, s), 0.98 (3 H, d,  $J = 6.8$  Hz), 1.02 (9 H, s), 1.07 (9 H, s), 1.08 (9 H, s), 1.35 (1 H, br s), 1.58 (1 H, m), 1.76 (1 H, m), 1.91 (1 H, m), 1.99 (1 H, m), 2.20 (1 H, dd,  $J = 8.7, 16.7$  Hz), 2.29 (1 H, dd,  $J = 10.2, 16.7$  Hz), 2.39 (1 H, m), 2.53 (1 H, dd,  $J = 4.2, 16.7$  Hz), 2.67 (1 H, m), 2.97 (1 H, dd,  $J = 2.2, 16.7$  Hz), 3.10 (1 H, m), 3.30 (1 H, m), 3.32 (3 H, s), 3.69 (1 H, dd,  $J = 6.0, 10.3$  Hz), 3.76 (1 H, m), 3.80 (1 H, dd,  $J = 3.5, 10.3$  Hz), 3.92 (1 H, m), 4.00 (1 H, m), 4.05 (1 H, d,  $J = 11.5$  Hz), 4.26 (1 H, m), 4.35 (1 H, d,  $J = 11.5$  Hz), 6.01 (1 H, d,  $J = 14.5$  Hz), 6.33 (1 H, dd,  $J = 7.8, 14.5$  Hz), 6.79 (2 H, d,  $J = 8.6$  Hz), 7.13 (2 H, d,  $J = 8.6$  Hz).
- The total synthesis of halichondrin B from the iodoolefin **13** has recently been completed, establishing the complete structure as illustrated.
- The bromide **12** was synthesized from (*S*)-(+)-methyl 3-hydroxy-2-methylpropionate (Aldrich) in approximately 40% overall yield, in 8 steps: 1. THP protection, 2. LAH reduction, 3. Swern oxidation, 4.  $\text{LiC}\equiv\text{C-TMS}$ , followed by chromatographic separation of two diastereomers, 5.  $\text{MPMO}(\text{C}=\text{NH})\text{CCl}_3\cdot\text{BF}_3\cdot\text{Et}_2\text{O}$ , 6. CSA/McOH, 7.  $\text{MsCl}/\text{Et}_3\text{N}$ , 8. LiBr.
- Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155-4156.

(Received in USA 20 December 1991)